Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Premenopausal bone loss: fact or artifact?

B J Riis1

  • 1Center for Clinical and Basic Research, Ballerup, Denmark.

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone·2018
Same author

Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study.

International journal of epidemiology·2016
Same author

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Osteoarthritis and cartilage·2015
Same author

OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.

Osteoarthritis and cartilage·2015
Same author

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

Bone·2012
Same author

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011
Same journal

Correction to: Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Letter to the Editor: multiplicity, microbiome interventions, and measurement biases in bone health biomarkers.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Association between myosteatosis and bone mineral density in postmenopausal women.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Author response to the letter to the editor regarding "Hip Response to Romosozumab in Glucocorticoid Users: Beyond Systemic Bone Turnover Markers".

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Revisiting the Osteoporosis Self-Assessment Tool (OST): evidence from a multi-cohort study in Asia supporting age-dependent thresholds.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
See all related articles

Women experience minor bone loss before menopause, but it is not clinically significant. This contrasts with greater bone loss after menopause, contributing to higher fracture risk in older women.

Area of Science:

  • Bone biology and aging
  • Endocrinology
  • Osteoporosis research

Background:

  • Bone mass is critical for bone strength, with sex differences impacting fracture risk.
  • Women have lower peak bone mass and faster bone loss rates than men.
  • The extent of bone loss in premenopausal women remains a subject of debate.

Purpose of the Study:

  • To review cross-sectional and longitudinal studies on premenopausal bone loss.
  • To determine the clinical significance of bone loss in women before menopause.

Main Methods:

  • Analysis of cross-sectional studies (with and without menopausal status data).
  • Review of longitudinal studies tracking women through menopause.
  • Statistical evaluation of bone density changes.

Related Experiment Videos

Main Results:

  • A minor, statistically significant trabecular bone loss may occur before menopause.
  • This premenopausal bone loss is generally of no clinical significance.
  • Significant bone loss and increased fracture risk are more pronounced after menopause in women.

Conclusions:

  • Premenopausal bone loss in women is likely minimal and not clinically relevant.
  • Postmenopausal bone loss is the primary driver of increased osteoporosis risk in women.
  • Understanding these sex differences is crucial for managing osteoporosis.